Executive Director

Mr. Ji Guangfei (Chairman and Chief Executive Officer)

Mr. Ji joined the Group in April 2025 and currently serves as the Company's executive Director, the Chairman of the Board, Chief Executive Officer, the chairman of the Company's nomination committee, and a member of the Company's remuneration committee. He has dedicated over 25 years to corporate management and investment operations and accumulated profound experience in various fields including medical health, financial investment and energy, etc.. He possesses extensive resources integration ability to promote in-depth integration of industries. Mr. Ji currently serves as the chairman of Tong Ren Tang International Group and plays a key role in the corporate management and strategic decision-making, leading the group to steady development. Concurrently, Mr. Ji also serves as the director of various companies, including Top Eminent Invest Co., Limited (an entity incorporated in Hong Kong), Top Eminent Investment (Singapore) Pte Ltd., Beijing Tong Ren Tang USA Inc., Beijing Tong Ren Tang Europe Holding B.V., and The Herb Booth Pty Ltd., etc., contributing to the corporate development with his rich experience and outstanding leadership. Mr. Ji obtained an Executive Master of Business Administration (EMBA) degree from the Chinese University of Hong Kong in 2015.

Ms. Li Jiang (Deputy Chairman)

Ms. Li joined the Group in 2022 as the head of healthcare and currently serves as the Company's executive Director. She has over 30 years of experience in the retail management of medicines and in the operations of healthcare products and medicines manufacturing. Prior to joining the Group, Ms. Li served as the vice general manager of Beijing Tong Ren Tang Chuan Chiong Enterprises Consultancy Co., Ltd. from 2000 to 2021, where she was responsible for the operation and management of the Chongwenmen Pharmaceutical Store of Tong Ren Tong. From 2005 to 2021, Ms. Li was also the deputy vice general manager of Beijing Tong Ren Tang Pharmaceutical Co., Ltd., where she oversaw the supervision and management of Chinese medicine factories. Ms. Li holds a Bachelor's degree specializing in trade and economics from Renmin University of China, which she obtained in 1987, and an EMBA degree from The University of Texas at Arlington in 2005.

Mr. Zhang Huanping

Mr. Zhang joined the Group in 2023 as a consultant to provide professional advice on ODM product development and currently serves as the Company's executive Director and the chairman of the Company's corporate governance committee. He has over 40 years of experience in the production of Chinese medicine products. Prior to joining the Group, Mr. Zhang served as the executive director and chief executive officer of Beijing Tong Ren Tang Chinese Medicine Company Limited (Hong Kong Stock Code: 3613), where he was primarily responsible for production. He joined Beijing Tong Ren Tang group in 1979 and previously held the positions of deputy manager of the Chinese medicine factory and the medicine wine factory at Tong Ren Tang, as well as an executive director of Tong Ren Tang Technologies Co., Ltd.. Mr. Zhang graduated from the Correspondence Institute of the Party School of the Central Committee of the Chinese Communist Party, majoring in economic management, in 2000. He was conferred the title of Pharmacist-in-Charge by the Beijing Intermediate Professional Technical Titles Evaluation Committee in 2002.

Non-executive Directors

Mr. Li Jiong

Mr. Li has been appointed as a non-executive Director since 21 May 2018. He concurrently serves as a director of CITIC Securities Overseas Investment and CITIC Securities International USA, LLC., as well as a chief treasury officer of CITIC Securities. After Mr. Li joined CITIC Securities in 1996, he had served as the manager of the international cooperation division of the information centre of China International Trust Investment Corporation (renamed to CITIC Group Corporation), manager of development department of CITIC International Cooperation Co., Ltd., manager of the bond department, deputy general manager of the treasury department and person-in- charge of the treasury department of CITIC Securities. Mr. Li obtained a Bachelor's degree in International Finance from the University of International Business and Economics in 1992 and a Master's degree in Business Administration from Tsinghua University in 2000.

Mr. Yuan Feng

Mr. Yuan joined the Group in June 2019 and currently serves the Company's non-executive Director. He is the director of the planning and finance department of CITIC Securities Company Limited (“CITIC Securities”), the controlling shareholder (as defined in the Listing Rules) of CITIC Securities International Company Limited, which has been a shareholder of the Company since April 2019. He is also the chief financial officer of CITIC CLSA group, a wholly-owned subsidiary group of CITIC Securities. Mr. Yuan previously worked as a senior accountant in the finance department of CITIC Corporation Limited from February 2015 to April 2019, and as an audit manager at Deloitte Touche Tohmatsu from July 2008 to July 2014. He obtained his Master's degree in world economics from the University of International Relations in 2008 and has been a member of The Chinese Institute of Certified Public Accountants since 2014.

Mr. Chung Cheuk Fan Marco

Mr. Chung joined the Group in July 2021 and currently serves as the Company's non-executive Director. He is the Group Head of Legal of the CITIC CLSA group. Prior to joining the CITIC CLSA group, Mr. Chung worked at Morgan Stanley between November 2011 to April 2021 holding various positions including regional head of legal for the investment management private funds business; regional head of legal for the investment banking mergers and acquisitions business; and the regional chief operating officer for the investment management private funds business. Prior to joining Morgan Stanley, Mr. Chung worked as an attorney (specializing in company law) at Slaughter and May’s London and Hong Kong offices between 2004 to 2011. Mr. Chung is a qualified attorney in England & Wales, Hong Kong, Australia (New South Wales) and New Zealand. Mr. Chung obtained a Bachelor of Laws and Commerce conjoint degree from the University of Auckland. Mr. Chung has been appointed to the Shenzhen Court of International Arbitration Panel of Arbitrators and the South China International Arbitration Center (Hong Kong) Panel of Arbitrators.

Independent non-executive Directors

Mr. Zhou Zuyu (Lead INED)

Mr. Zhou joined the Group in April 2025. He serves as the Company's independent non-executive Director, the Lead INED, and the chairman of the Company's remuneration committee. He is also a member of the Company's audit committee, nomination committee and corporate governance committee. He served as a managing director and head of healthcare investment banking for Asia Pacific at Credit Suisse. Prior to 2021, he was a managing director and head of healthcare investment banking at CITIC CLSA group, as well as a senior vice president of investment banking at CITIC Securities. He graduated from Peking University's Guanghua School of Management in 2004 with a Master's degree in finance.

Ms. Hu Zhaoxia

Ms. Hu joined the Group in June 2019. She serves as the Company's independent non-exeuctive Director, the chairman of the Company's audit committee, and is a member of the Company's remuneration committee and nomination committee. From 2012 to September 2015, Ms. Hu served as the chief financial officer of (Zanhua (China) Equipment Leasing Co., Ltd.*) 贊華（中國）設備租賃有限公司. Prior to this, from October 1978 to January 2012, Ms. Hu worked as deputy director of the accounting system division, deputy general manager and director of the accounting division of the finance and accounting department of the Head Office of Bank of China; deputy manager of the accounting department and assistant general manager of Bank of China London Branch; deputy general manager of Bank of China Sydney Branch; chief financial officer of the retail banking business department of Bank of China and senior supervisor of the office of the board of supervisors of the Head Office of Bank of China. Ms. Hu graduated from Tianjin University of Finance and Economics with major in Finance in 1978 and obtained her senior accountant qualification, which was granted by the committee of assessment of Bank of China in 1992.

Mr. Lyu Aiping

Mr. Lyu joined the Group in April 2025. He serves as the Company's independent non-executive Director and is a member of the Company's audit committee, nomination committee, and corporate governance committee. He is currently Vice-President (Research and Development) and Dr. Kennedy Y.H. Wong Endowed Chair Professor in Chinese Medicine at Hong Kong Baptist University. He is also the Foreign Member of Academia Europaea and is currently serving as an independent non-executive director for a company listed on the Stock Exchange, namely Kaisa Health Group Holdings Limited (Stock Code: 876). Mr. Lyu's current research focuses on the field of systems medicine, where he integrates Chinese medicine and Western medicine while applying advanced techniques in life sciences and data sciences. Specifically, he is dedicated to the novel re-classification of rheumatoid arthritis, aiming to identify more precise therapeutics based on new subgroupings of patients through a combination treatment approach using existing drugs. His research has further delved into the dynamics of network biomarkers for re-classification and the interaction of combined drugs for precise treatment. Mr. Lyu's contributions to academia are substantial, with approximately 600 academic papers published in renowned journals such as Nature Medicine, Nature Review in Drug Discovery, Nature Communications, and Briefings in Bioinformatics, covering a wide range of areas in integrative medicine. His research excellence has been acknowledged with the Highly Cited Researcher award in 2023 by Clarivate Analytics.

* for identification purpose only